Influence of COMT inhibition on levodopa pharmacology and therapy

Neurology

Volumn 50, Issue 5 SUPPL. 5, 1998, Pages

  Goetz, Christopher G ^a,b  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b RUSH MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 O METHYLDOPAMINE; 3,4 DIHYDROXYPHENYLACETIC ACID; AROMATIC LEVO AMINO ACID DECARBOXYLASE; BENSERAZIDE PLUS LEVODOPA; CARBIDOPA PLUS LEVODOPA; CATECHOL METHYLTRANSFERASE; CATECHOL METHYLTRANSFERASE INHIBITOR; DOPAMINE; ENTACAPONE; HOMOVANILLIC ACID; LEVODOPA; S ADENOSYLMETHIONINE; TOLCAPONE;

ARTICLE; BLOOD BRAIN BARRIER; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG METABOLISM; ENZYME INHIBITION; HUMAN; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL;

EID: 0031900188     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.50.5_suppl_5.s26     Document Type: Article

References (22)

1. Männistö PT, Ulmanen I, Lundström K, et al. Characteristics of catechol O-methyl-transferase (COMT) and properties of selective COMT inhibitors. Prog Drug Res 1992;39:291-350.
2. Roberts JW, Cora-Locatelli G, Bravi D, Amantea MA, Mouradian MM, Chase TN. Catechol-O-methyltransferase inhibitor tolcapone prolongs levodopa/carbidopa action in parkinsonian patients. Neurology 1993;43:2685-2688.
3. Merello M, Lees AJ, Webster R, Bovingdon M, Gordin A. Effect of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, on the motor response to acute treatment with levodopa in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 1994;57:186-189.
4. Nutt JG, Woodward WR, Beckner RM, et al. Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology 1994;44:913-919.
5. Zürcher G, Dingemanse J, Da Prada M. Ro 40-7592, a potent inhibitor of extracerebral and brain catechol-O-methyltransferase: preclinical and clinical findings. In: Agnoli A, Campanella G, eds. New developments in therapy of Parkinson's disease. Rome: John Libby CIC, 1991:37-43.
6. Kaakkola S, Gordin A, Männistö PT. General properties and clinical possibilities of new selective inhibitors of catechol O-methyltransferase. Gen Pharmacol 1994;25:813-824.
7. Prous J, Rabasseda X, Castañer J. Entacapone. Drugs Future 1994;19:641-645.
8. Napolitano A, Zürcher G, Da Prada M. Effects of tolcapone, a novel catechol-O-methyltransferase inhibitor, on striatal metabolism of L-DOPA and dopamine in rats. Eur J Pharmacol 1995;273:215-221.
9. 2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science 1990;250:1429-1432.
10. Jorga KM, Sedek G. Effect of the novel COMT-inhibitor tolcapone on L-dopa pharmacokinetics when combined with different Sinemet formulations [Abstract]. Neurology 1995;45(suppl 4):A291.
11. Nutt JG. Pharmacokinetics of levodopa. Clinical implications. In: Koller WC, ed. Handbook of Parkinson's disease. 2nd ed. New York: Marcel Dekker, 1987:339-354.
12. Guttman M, Leger G, Cedarbaum JM. 3-O-methyldopa administration does not alter fluordopa transport into the brain. Ann Neurol 1992;31:638-643.
13. Da Prada M, Zürcher G, Kettler R, Dingemanse J, Jorga K, Dubuis R. Remodeling the kinetics and dynamics of levodopa therapy in Parkinson's disease by inhibiting MAO-B with lazabemide and COMT with tolcapone. In: Poewe W, Lees AJ, eds. Levodopa - the first twenty-five years. Basel: Editions Roche, 1994:99-117.
14. Keränen T, Gordin A, Harjola V-P, et al. The effect of catechol-O-methyl transferase inhibition by entacapone on the pharmacokinetics and metabolism of levodopa in healthy volunteers. Clin Neuropharmacol 1993;16:145-156.
15. Da Prada M. Enhanced benefit in levodopa therapy by MAO-B and COMT inhibition. In: Battistin L, Oertel W, eds. Drug treatment of Parkinson's disease: levodopa 20 years later. Roche satellite symposium at the 11th International Symposium on Parkinson's Disease; March 28, 1994, Rome.
16. Ahtila S, Kaakkola S, Gordin A, et al. Effect of entacapone, a COMT inhibitor, on the pharmacokinetics and metabolism of levodopa after administration of controlled-release levodopa-carbidopa in volunteers. Clin Neuropharmacol 1995;18:46-57.
17. Törnwall M, Kaakola S, Tuomainen P, Kask A, Männistö PT. Comparison of two new inhibitors of catechol-O-methylation on striatal dopamine metabolism: a microdialysis study in rats. Br J Pharmacol 1994;112:13-18.
18. Zürcher G, Colzi A, Da Prada M. Ro 40-7592: inhibition of COMT in rat brain and extracerebral tissues. J Neural Transm Suppl 1990;32:375-380.
19. Zürcher G, Dingemanse J, Da Prada M. Potent COMT inhibition by Ro 40-7592 in the periphery and in the brain. Preclinical and clinical findings. Adv Neurol 1993;60:641-647.
20. Da Prada M, Borgulya J, Napolitano A, Zürcher G. Improved therapy of Parkinson's disease with tolcapone, a central and peripheral COMT inhibitor with an S-adenosyl-L-methionine-sparing effect. Clin Neuropharmacol 1994; 17(suppl 3):S26-37.
21. Moreau J-L, Borgulya J, Jenck F, Martin JR. Tolcapone: a potential new antidepressant detected in a novel animal model of depression. Behav Pharmacol 1994;5:344-350.
22. Guttman M. COMT inhibition: new hopes in the management of Parkinson's therapy. Focus Parkinson's Dis 1995;7:58-61.